

# FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response...	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Eansor Norman David		2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [TECH]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) _____ SVP - Novus Biologicals	
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 07/01/2017		
8100 SOUTHPARK WAY, A-8			4. If Amendment, Date Original Filed(Month/Day/Year)		
(Street) LITTLETON, CO 80120			6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		
(City) (State) (Zip)			Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned		

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	07/01/2017		F		534	D	\$ 117.5	3,402	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					
Restricted Stock Units	(1)							(2)	(2)	Common Stock	1,500	1,500	D	
Restricted Stock Units	(3)							(4)	(4)	Common Stock	2,287	2,287	D	
Stock Option (Right to Buy)	\$ 108.49							(5)	08/07/2022	Common Stock	12,500	12,500	D	
Stock Option (Right to Buy)	\$ 108.49							(2)	08/07/2022	Common Stock	9,375	9,375	D	
Stock Option (Right to Buy)	\$ 94.35							(6)	08/12/2021	Common Stock	15,000	15,000	D	
Stock Options (Right to buy)	\$ 106.59							(7)	08/18/2023	Common Stock	18,819	18,819	D	
Stock Options (Right to buy)	\$ 106.59							(4)	08/18/2023	Common Stock	14,114	14,114	D	

### Reporting Owners

\_\_\_\_\_

Reporting Owner Name / Address			Relationships	
	Director	10% Owner	Officer	Other
Eansor Norman David 8100 SOUTHPARK WAY, A-8 LITTLETON, CO 80120			SVP - Novus Biologicals	

## Signatures

/s/ Kathy Backes as Attorney-in-Fact for David N. Eansor pursuant to Power of Attorney previously filed.		07/05/2017
<small>**Signature of Reporting Person</small>		<small>Date</small>

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- (2) Vests in full or in part on 8/7/18 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (3) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- (4) Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (5) 3,125 shares vest on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19.
- (6) 3,750 shares vest on each of 8/12/15, 8/12/16, 8/12/17 and 8/12/18.
- (7) Vests 4,705 shares on 8/18/17, 8/18/18, and 8/18/19 and 4,704 shares on 8/18/20.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.